Positive results from 5-7 years' follow-up of the first Episealer® Knee patients in a Swedish multicentre clinical trial
Episurf Medical (Nasdaq: EPIS B) today announces that the company has been informed about positive results in a clinical study with follow-up at 5-7 years of the 10 first patients to receive an Episealer® Knee implant. The principle investigator, MD PhD A. Stålman at Capio Artro Clinic in Stockholm, will now compile the results from this study for submission to a scientific journal.
The study is a multicentre study performed at three Swedish clinics. It is a continuation of a previous study (“No implant migration and good subjective outcome of a novel customized femoral resurfacing metal implant for focal chondral lesions”) by A. Stålman et al., published in the scientific journal Knee Surgery, Sports Traumatology, Arthroscopy in 2018.
The patients in the study received an Episealer® Knee implant as treatment of a focal cartilage defect in the knee during December 2012 to November 2014. This study now concludes that the positive results at 24 months' follow-up previously presented, remain unchanged at an average follow-up time of 75 months, and that no implant revisions have been performed.
“This is the first clinical study with 5-7 years' follow up from the use of the Episealer® knee implants. The fact that the positive results that are shown at the 24 months’ follow-up remain over time, points to the conclusion that our technology is not only a temporary solution. Stakeholders, including our customers, insurance companies and healthcare providers, have requested this type of clinical evidence before approving the Episealer® technology within their standard treatment algorithm. We are delighted to hear about the positive results from this independent study, and we hope to see these results published shortly”, says Pål Ryfors, CEO, Episurf Medical.
“This news is superbly satisfactory. Not only does the Episealer® technology show very low revision rates, as previously disclosed, but good clinical results also remain over time which is another imperative characteristic of any excellent medical technology”, says Prof. Leif Ryd, Senior Medical Advisor, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 8 September 2020.
Tags: